Abstract:
본 발명은 장구채 추출물 또는 이로부터 분리된 (-)-보르네시톨((-)-bornesitol)을 유효성분으로 함유하는 세포 노화 억제용 조성물에 관한 것으로, 아드리아마이신에 의해 유도되는 것을 특징으로 하는 세포 노화 억제용 약학 조성물을 제공한다. 이렇게 섬유아세포 또는 제대정맥혈관내피세포의 세포노화 과정을 억제함으로써 노화관련 질환, 예를 들어 피부노화, 류마티스성 관절염, 골관절염, 간염, 만성 피부손상 조직, 동맥경화, 전립샘 증식증 및 간암 등과 같은 질환 치료에 유용하게 사용될 수 있다. 또한 세포노화를 저해할 수 있는 항노화 기능성 식품, 항혈관노화 약물 개발, 화장품 개발에 활용될 수 있을 것으로 기대된다.
Abstract:
본 발명은 선복화 추출물, 이로부터 분리된 브리타닌(britanin) 또는 이들의 혼합물을 유효성분으로 함유하는 섬유아세포 노화 억제용 약학 조성물에 관한 것으로, 아드리아마이신에 의해 유도되는 것을 특징으로 하는 섬유아세포의 노화 억제용 약학 조성물을 제공한다. 이렇게 사람 섬유아세포의 세포노화 과정을 억제함으로써 노화관련 질환, 예를들어 피부노화, 류마티스성 관절염, 골관절염, 간염, 만성 피부손상 조직, 동맥경화, 전립샘 증식증 및 간암 등과 같은 질환 치료에 유용하게 사용될 수 있다. 또한, 세포노화를 저해할 수 있는 항노화 기능성 식품, 항혈관노화 약물 개발, 화장품 개발에 활용될 수 있을 것으로 기대된다.
Abstract:
The present invention relates to a composition for inhibiting cellular senescence which includes (-)-loliolide as an active ingredient. The present invention provides the composition for inhibiting cellular senescence which inhibits senescence of fibroblast or replicative senescence which is induced by adriamycin. More specifically, the (-)-loliolide is isolated from Polygoniavicularisherba extract. By inhibiting cellular senescence of human fibroblast, the composition for inhibiting cellular senescence which includes (-)-loliolide as an active ingredient can be used for senescence related diseases such as aging of the skin, rheumatoid arthritis, degenerative arthritis, hepatitis, chronic skin tissue damage, hardening of the artery, benign prostatic hyperplasia, liver cancer, and the likes.
Abstract:
본 발명은 안트라퀴논 유도체를 유효성분으로 함유하는 알레르기성 질환 예방 및 치료용 약학조성물에 관한 것으로, 보다 상세하게는 천연물에서 분리한 안트라퀴논 유도체들은 알러지 반응 및 천식반응에 관련이 있는 사이클로옥시게나제-2(COX-2) 의존적인 프로스타글란딘 D 2 (PGD 2 ) 생성을 억제하고, 5-리폭시게나제(5-LOX) 의존적인 류코트리엔 C 4 (LTC 4 ) 생성을 억제하며, 동시에 비만세포로부터 탈과립 반응을 억제하였다. 그리고 PMA/A23187로 유도한 비만세포에서 종양괴사인자-α(TNF-α), 인터루킨-6(IL-6) 및 IL-1β의 생성을 억제하였다. 또한 IgE/항원으로 유도한 알레르기 동물모델에서도 그 효과가 입증됨으로써 천식을 포함한 다양한 알레르기 질환의 예방 및 치료제로서 유용하게 사용될 수 있다.
Abstract:
PURPOSE: A pharmaceutical composition containing porifera extract for preventing and treating inflammatory diseases is provided to suppress COX-2-dependent prostaglandin 2. CONSTITUTION: A pharmaceutical composition for preventing and treating inflammatory diseases contains 0.1-50 weight parts of Porifera extract as an active ingredient. The porifera extract is isolated using water, hexane, alcohol of C1-C4, ethyl acetate, or mixture thereof. The extract is a hot water extract. A health food for treating inflammatory diseases contains porifera extract as an active ingredient. The health food is manufactured in the form of powder, granule, tablet, capsule, syrup, or beverage.
Abstract:
PURPOSE: A composition containing an extract of a sea sponge is provided to prevent and treat diseased occurring from matrix metalloproteinase(MMP)-9 OR MMP-2 which directly take parts in vascularization. CONSTITUTION: A composition for inhibiting MMP-9 or MMP-2 contains an extract of a sea sponge as an active ingredient. The sea sponge is selected from the group consisting of a cliona celata, a callyspongia elegans, a calcarea, a glass sponges, a demospongiae, a euspongia officinalis, a keratosa, a halichondria japonica, or a h. panacea. The extract is a polar or a non-polar solvent extraction of the sea sponge. The formulation of a health food containing the composition includes powder, granule, capsules, tablets, or liquid.
Abstract translation:目的:提供含有海绵提取物的组合物,用于预防和治疗基质金属蛋白酶(MMP)-9 OR MMP-2发生的病变,直接影响血管形成。 构成:用于抑制MMP-9或MMP-2的组合物含有作为活性成分的海绵的提取物。 海绵选自克隆氏细丝,丝氨酸杆菌,钙质石,玻璃海绵,呼吸龙骨,龙胆,龙胆,枸杞,或h。 灵丹妙药。 提取物是海绵的极性或非极性溶剂萃取。 含有该组合物的保健食品的配方包括粉末,颗粒,胶囊,片剂或液体。
Abstract:
A health care composition for the prevention and alleviation of inflammatory, allergy and asthma diseases comprising saucerneol B isolated from Saururus chinensis is provided to inhibit activity of 5-lipoxygenase and cyclooxygenase-2, production of prostaglandin D2, degranulation in a mast cell, production of nitric oxide radicals, expression of iNOS(inducible nitric oxide synthase) and activity of MMP-9(matrix metallopeptidase 9) without side effects. A health care composition for the prevention and alleviation of inflammatory, allergy and asthma diseases comprises 0.01-99.9%, preferably 0.1-90% of saucerneol B represented by the formula(I) which is isolated from Saururus chinensis by extracting Saururus chinensis with water, C1-C4 lower alcohol or a mixed solvent, suspending the extract in distilled water, extracting the suspension with hexane, ethylacetate or chloroform, and subjecting the non-polar solvent extract to silica gel column chromatography. The daily dosage of saucerneol B is 0.0001-100 mg/kg.
Abstract:
A composition for the prevention and treatment of inflammatory, allergy or blood circulatory diseases comprising a SCE25-20 compound isolated from Saururus chinensis is provided to inhibit activity of 5-lipoxygenase causing allergy and asthma, production of cyclooxygenase-2 dependent prostaglandin D2, degranulation in mast cell, production of nitric oxide radical, expression of iNOS(inducible nitric oxide synthase), and activity of MMP-9(matrix metalloproteinase-9) associated with arteriosclerosis and vascular diseases. The composition for the prevention and treatment of inflammatory, allergy or blood circulatory diseases comprises 0.01-99.9%, preferably 0.1-90% of the SCE25-20 compound isolated from Saururus chinensis, represented by the formula(1) which is prepared by cutting roots, leaves or stems of Saururus chinensis, extracting the fragments of Saururus chinensis with a solvent selected from water, C1-C4 lower alcohol such as methanol at 20-30 deg.C for 1 hour to 10 days, filtering and concentrating the extract of Saururus chinensis under reduced pressure; fractionating the Saururus chinensis extract with n-hexane, ethylacetate, n-butanol and water, sequentially, and subjecting the fraction to chromatography.